Navigation Links
Caspase Inhibitor Enters Clinical Trial In Islet Transplantation As Treatment For Diabetes
Date:7/19/2012

SAN DIEGO and EDMONTON, Alberta, July 19, 2012 /PRNewswire/ -- Conatus Pharmaceuticals Inc. and the University of Alberta announced today the treatment of the first patient in an investigator-initiated islet cell transplant Phase I/II trial of emricasan (IDN-6556), a pan-caspase inhibitor.  The objective of the trial is to determine safety, achievement and maintenance of insulin independence and to obtain preliminary data on the efficacy of emricasan to maintain adequate immunological protection against both allo- and autoimmunity of islet cell transplant recipients.  The sponsor of the trial is the University of Alberta and the principal investigator is A. M. James Shapiro, M.D., Ph.D.

"Preclinical studies support the use of a pan-caspase inhibitor therapy to broaden the availability of clinical islet transplantation.  Enhancing islet engraftment post-transplant should prolong graft longevity, resulting in a more quiescent immunological state and thereby enhancing long-term rates of insulin independence.  Inhibition of islet apoptosis in the immediate post-transplant period may reduce the amount and intensity of anti-rejection therapy, accelerating 'accommodation' and drug minimization.  If this could be achieved, or if stable immunological tolerance was enhanced through emricasan treatment, islet transplantation would be potentially safer and therefore more available to a broader spectrum of patients with type 1 diabetes," said Dr. Shapiro.  "Over 750 islet transplantations are now carried out each year in 30 active centers worldwide.  Diabetologists, funding organizations and regulatory agencies recognize islet transplantation as an effective therapy to prevent episodic hypoglycemia, correct glycated hemoglobin and reduce risk of secondary diabetic complication."

"As Conatus pursues the development of emricasan on our own in liver disease, I am pleased to support new treatment paradigms in diabetes.  I
'/>"/>

SOURCE Conatus Pharmaceuticals Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Grifols Initiates Safety Study of Inhaled Alpha1-Proteinase Inhibitor (Human) Following Orphan Drug Designation for Cystic Fibrosis
2. Kinase Inhibitors Market to Reach $11.6 Billion in US, $40.3 Billion Globally by 2016
3. Global Angiogenesis Inhibitors and Stimulators Industry
4. Global Markets for Enzyme Inhibitors
5. Emerging Markets for Enzyme Inhibitors Surge, To Grow More Than 50% by 2016
6. Debiopharm and Ascepion Pharmaceuticals, Inc. Announce an Exclusive License Agreement for the Development and Commercialisation of the Dual-Targeting Kinase Inhibitor, ASP-08126 (Debio 1144), for the Treatment of Oncology Diseases
7. Lilly and Incytes Oral JAK1 and JAK2 Inhibitor, Baricitinib, Showed Positive Results in Phase IIb Study in Patients with Active Rheumatoid Arthritis
8. Ambit Biosciences and Teva Announce Clearance of an Investigational New Drug (IND) Application for CEP-32496, A Novel BRAF(V600E) Inhibitor
9. CSL Behring Initiates Study of Subcutaneous Administration of C1-esterase Inhibitor in Patients with Hereditary Angioedema
10. Spine Pain Management Opens Two Additional Affiliate Diagnostic Centers in Florida
11. ApolloMed ACO Selected To Participate In A Transformative New Initiative Sponsored by the Centers for Medicare and Medicaid Services
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... July 29, 2015  Unilife Corporation ("Unilife" or the ... developer, manufacturer and supplier of injectable drug delivery systems, ... that provides the Company with flexibility and control to ... has signed an equity purchase agreement for up to ... a Chicago -based institutional investor, which ...
(Date:7/29/2015)... 2015  Nektar Therapeutics (Nasdaq: NKTR ) will announce ... 2015 on Wednesday, August 5, 2015, after the close of ... executive officer, will host a conference call to review the ... Time (PT). The press release and a ... through a link that is posted on the home page ...
(Date:7/29/2015)... Calif. , July 29, 2015 Daiichi ... Daiichi Sankyo Group, announced today that The New ... results demonstrating that the investigational drug, PLX3397, an oral ... patients with tenosynovial giant cell tumor (TGCT), a rare, ... Following phase 1 dose-escalation, which evaluated the ...
Breaking Medicine Technology:Unilife Announces Multifaceted Financing Strategy 2Unilife Announces Multifaceted Financing Strategy 3Unilife Announces Multifaceted Financing Strategy 4Unilife Announces Multifaceted Financing Strategy 5Nektar to Announce Financial Results for the Second Quarter 2015 on Wednesday, August 5, 2015, After Close of U.S.-Based Financial Markets 2Nektar to Announce Financial Results for the Second Quarter 2015 on Wednesday, August 5, 2015, After Close of U.S.-Based Financial Markets 3Daiichi Sankyo and Plexxikon Announce Study Published in NEJM Demonstrates PLX3397 Induced Prolonged Tumor Regression in Tenosynovial Giant Cell Tumor (TGCT) in Most Patients 2Daiichi Sankyo and Plexxikon Announce Study Published in NEJM Demonstrates PLX3397 Induced Prolonged Tumor Regression in Tenosynovial Giant Cell Tumor (TGCT) in Most Patients 3Daiichi Sankyo and Plexxikon Announce Study Published in NEJM Demonstrates PLX3397 Induced Prolonged Tumor Regression in Tenosynovial Giant Cell Tumor (TGCT) in Most Patients 4Daiichi Sankyo and Plexxikon Announce Study Published in NEJM Demonstrates PLX3397 Induced Prolonged Tumor Regression in Tenosynovial Giant Cell Tumor (TGCT) in Most Patients 5
(Date:7/30/2015)... ... July 30, 2015 , ... 24/7 Care At Home, a high-quality provider ... recently announced that the Centers for Medicare and Medicaid (CMS) have awarded its agency ... providers. 24/7 Care At Home’s agency is one of three top Orange County agencies ...
(Date:7/30/2015)... ... July 30, 2015 , ... The need for accessibility is never greater ... comfort to patients as well as visiting friends and family during these critical moments, ... , The stations - powered by ChargeItSpot , a Philadelphia-based startup that recently ...
(Date:7/30/2015)... NJ (PRWEB) , ... July 30, 2015 , ... ... continues to expand, as the company and UCLA’s Jonsson Comprehensive Cancer Center ... OncLive announced today. With the new collaboration, OncLive’s editorial and marketing groups will ...
(Date:7/30/2015)... , ... July 30, 2015 , ... ... Zaichik Creates New Tool That Increases Training Capability , World renown ... tool called Zejax ( http://www.Zejax.com ), that dramatically increases a person’s training capability. ...
(Date:7/30/2015)... (PRWEB) , ... July 30, 2015 , ... ... announced today that the latest issue of Inclusive™ magazine, its multimedia publication focused ... The digital edition of the new issue, Volume 6, Issue 2, as well ...
Breaking Medicine News(10 mins):Health News:24/7 Care At Home Earns a 5-Star Rating from the Centers for Medicare and Medicaid (CMS) 2Health News:Hospitals Add Phone Charging Stations as an Amenity for Patients and Visitors 2Health News:UCLA Jonsson Comprehensive Cancer Center Teams with OncLive® as a Strategic Alliance Partner 2Health News:UCLA Jonsson Comprehensive Cancer Center Teams with OncLive® as a Strategic Alliance Partner 3Health News:UCLA Jonsson Comprehensive Cancer Center Teams with OncLive® as a Strategic Alliance Partner 4Health News:Zejax is a Revolutionary New Way of BodyWeight Training Without Weights 2Health News:Glidewell Laboratories Puts Out Latest Issue of Dental Implant Magazine Inclusive™ 2Health News:Glidewell Laboratories Puts Out Latest Issue of Dental Implant Magazine Inclusive™ 3Health News:Glidewell Laboratories Puts Out Latest Issue of Dental Implant Magazine Inclusive™ 4
... children and adolescents in the United States had physician-diagnosed ... major national study called SEARCH for Diabetes in Youth. ... among youth under the age of 20 ever conducted ... M.S., associate professor of epidemiology and prevention at Wake ...
... antibiotic shows early promise as an anti-cancer agent, inhibiting ... tumors, // according to researchers at the University of ... appear in the Oct. 1 issue of Cancer Research. ... to be over-expressed in cancer cells to screen for ...
... to rebuild after years of dictatorship and war, Iraqi ... // in treating many of the most serious injuries ... important step forward was last year's "Kuwait Plast 2005" ... and American counterparts in a 5-day exchange of surgical ...
... of Standards and Technology (NIST) are developing a robotic ... powered mobility and the ability, depending on patient status, ... without assistance. ,The lifting ability of the system, ... Position and Rehabilitation), also should significantly reduce caregiver and ...
... (TPVs) are more likely to suffer severe, persistent ... permanent protection visas (PPVs) // , specialist trauma ... post-traumatic stress disorder (PTSD) and depression are much ... holders, mental health professionals from the Sydney-based Service ...
... severe gastroenteritis should now be made available to all ... of the Medical Journal of Australia. // ... effective tool to prevent a common, miserable disease affecting ... say in an editorial. ,“Rotavirus vaccine is ...
Cached Medicine News:Health News:One in 523 Children and Adolescents Have Diabetes 2Health News:One in 523 Children and Adolescents Have Diabetes 3Health News:Antibiotic Inhibits Cancer Gene Activity 2Health News:Journal of Craniofacial Surgery Publishes Research by Iraqi Surgeons 2Health News:Robot Wheelchair Maybe Helpful for Wheelchair-dependent Patients 2Health News:Detention, Uncertainty take their Toll on the Mental Health of Refugees 2Health News:Experts Call for Rotavirus Vaccine for All 2
MBP's extra long 200 L pipet tip will reach the bottom of large tubes and vials, preventing your pipettor from contacting the sample container....
... is an immunometric ('sandwich') EIA for ... human serum or plasma. LH in ... monoclonal anti-LH antibodies directed at different ... magnetic particles and the other is ...
... is an HPLC system designed to provide ... levels and aid in the comprehensive identification ... results for glycemic control., ,The A1c assay ... with the accuracy of boronate affinity columns. ...
... of the fastest blood gas ... care situations on the market. ... lung function testing. The ... quick and reliable assessment of ...
Medicine Products: